Advertisement

Chasing Rainbows? the Possibility of “Cure” in Patients with Colorectal Peritoneal Metastases Undergoing Cytoreductive Surgery and HIPEC—a Retrospective Study by INDEPSO

  • Aditi BhattEmail author
  • Praveen Kammar
  • Sanket Mehta
  • Dileep Damodaran
  • Shabber Zaveri
  • Mahesh D. Patel
  • Snita Sinukumar
  • Mukurdipi Ray
  • Ramakrishnan Seshadri
Original Article
  • 4 Downloads

Abstract

Cytoreductive surgery (CRS) and HIPEC results in a median disease-free survival (DFS) of 12–15 months, overall survival (OS) of 23–63 months, and cure in around 15% of patients with colorectal peritoneal metastases (CPM). The wide variation in OS may largely be attributed to different criteria for patient selection employed by different investigators. To evaluate outcomes of CRS and HIPEC for CPM in patients enrolled in the Indian HIPEC registry. A retrospective analysis of patients enrolled in the registry since its inception in March 2016 was performed. The impact of various prognostic factors on DFS and OS was evaluated. From Jan 2013 to Dec 2017, 68 patients underwent CRS with HIPEC at six Indian centers. The median PCI was nine [range 3–35]. Twenty-two (32.3%) had mucinous tumors. A CC-0 resection was performed in 53 (77.9%) and CC-1 in 14 (20.5%). The median DFS was 12 months [95% CI 11.037–12.963 months] and the median OS 25 months [95% CI 18.718–31.282]. The DFS was inferior in patients with right upper quadrant involvement (p = 0.02) and 90-day major morbidity (p = 0.002) and OS inferior in those with 90-day major morbidity (p < 0.001) and mucinous tumors with a PCI > 20. The DFS compares well with results obtained by pioneering teams but we have no “cured” patients. Better patient selection and utilization of systemic therapies could in the future improve the OS. There is a compelling need to identify subgroups of CPM that benefit from the addition of HIPEC to CRS.

Keywords

Colorectal cancer Peritoneal metastases Cytoreductive surgery HIPEC Mucinous tumors 

Notes

Compliance with Ethical Standards

Conflicts of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Goéré D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, Maggiori L, Dumont F, Ducreux M, Elias D (2013) Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 257:1065–1071CrossRefGoogle Scholar
  2. 2.
    Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al (2018) A UNICANCER phase III trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for col- orectal peritoneal carcinomatosis (PC): PRODIGE 7 [Internet]. J Clin Oncol. [cited 2018 Jul 17];36:LBA3503-LBA3503 Available from. http://ascopubs.org/doi/10.1200/JCO.2018.36.18_suppl.LBA3503
  3. 3.
    Baratti D, Kusamura S, Pietrantonio F, Guaglio M, Niger M, Deraco M (2016) Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review. Crit Rev Oncol Hematol 100:209–222CrossRefGoogle Scholar
  4. 4.
    Bhatt A, Mehta S, Quenet F. Multimodality treatment for colorectal peritoneal metastases. In book: Management of peritoneal metastases- cytoreductive Surgery, HIPEC and beyond  https://doi.org/10.1007/978-981-10-7053-212
  5. 5.
    Glehen O, Kwiatkofski F, Sugarbaker PH, Elias D et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284–3292CrossRefGoogle Scholar
  6. 6.
    Sluiter NR, Rovers KP, Salhi Y, Vlek SL, Coupé VMH, Verheul HMW, Kazemier G, de Hingh IHJT, Tuynman JB (2018) Metachronous peritoneal metastases after adjuvant chemotherapy are associated with poor outcome after cytoreduction and HIPEC. Ann Surg Oncol 25(8):2347–2356.  https://doi.org/10.1245/s10434-018-6539-x CrossRefGoogle Scholar
  7. 7.
    Péron J, Mercier F, Tuech JJ, Younan R, Sideris L, Gelli M, Dumont F, Le Roy B, Sgarbura O, Lo Dico R, Bibeau F, Glehen O, Passot G, on behalf BIG-RENAPE working groups (2018) The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. Surgery:S0039-6060(18)30483-5.  https://doi.org/10.1016/j.surg.2018.07.027
  8. 8.
    Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S et al (2017) Pri- mary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol 28:1862–1868CrossRefGoogle Scholar
  9. 9.
    Ubink I, van Eden WJ, Snaebjornsson P, Kok NFM, van Kuik J, van Grevenstein WMU, Laclé MM, Sanders J, Fijneman RJA, Elias SG, Borel Rinkes IHM, Aalbers AGJ, Kranenburg O (2018 Jan) Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br J Surg 105(2):e204–e211.  https://doi.org/10.1002/bjs.10788 CrossRefGoogle Scholar
  10. 10.
    BFact sheets by population-CRC India ASRs. [Online]. Available: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
  11. 11.
    Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, Dumont F, Elias D (2015) Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol 22:2958–2964CrossRefGoogle Scholar
  12. 12.
    Elias D, Bonnay M, Puizillou JM, Antoun S, Dermirdjian S, El Otomany A et al (2002) Heated intra- operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmaco- kinetics and tissue distribution. Ann Surg Oncol 13:267–272CrossRefGoogle Scholar
  13. 13.
    Van der Speeten K, Stuart OA, Chang D et al (2011) Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 68:147.  https://doi.org/10.1007/s00280-010-1460-4 CrossRefGoogle Scholar
  14. 14.
    Witkamp AJ, van Coevorden F, Kaag MM, van Slooten GW, Beijnen JB, Boot H et al (1998) Dose finding study of hyperthermic intraperitoneal chemotherapy with mitomycin C in patients with carcinosis of colorectal origin. Eur J Surg Oncol 24:214Google Scholar
  15. 15.
    Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, Fakih MG (2008) Significance of signet-ring cells in patients with colorectal cancer. Dis Colon Rectum 51:50–55CrossRefGoogle Scholar
  16. 16.
    United States Department of Public Health and Human Services, NIH, NCI: Common Toxicity Criteria for Adverse Events (CTCAE). National Cancer Institute, June 2010. http://evs.nci.nih.gov/ftp1/CTCAE_Vers._4.03_2010-06-14;_QuickReference_5x7.pdf
  17. 17.
    Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ III (2010) Cytoreductive surgery and hyperthermic intraperitoneal chemo- perfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 116:3756–3762.  https://doi.org/10.1002/cncr.25116
  18. 18.
    Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O (2010) Peritoneal colorec- tal carcinomatosis treated with surgery and periop- erative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63–68CrossRefGoogle Scholar
  19. 19.
    Saxena A, Yan TD, Morris DL (2010) A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg 34:70–78CrossRefGoogle Scholar
  20. 20.
    Glockzin G, Zeman F, Croner RS, Königsrainer A, Pelz J, Ströhlein MA, Rau B, Arnold D, Koller M, Schlitt HJ, Piso P (2018) Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: results of the prospective multicenter phase 2 COMBATAC Trial. Clin Colorectal CancerGoogle Scholar
  21. 21.
    Rovers KP, Simkens GA, Punt CJ, van Dieren S, Tanis PJ, de Hingh IH (2017) Perioperative systemic therapy for resectable colorectal peritoneal metastases: sufficient evidence for its widespread use? A critical systematic review. Crit Rev Oncol Hematol 114:53–62.  https://doi.org/10.1016/j.critrevonc.2017.03.028 CrossRefGoogle Scholar
  22. 22.
    Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O, Cotte E (2012) Iterative procedures combining cytoreductive surgery with hyperther- mic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol 106(2):197–203CrossRefGoogle Scholar
  23. 23.
    Passot G, You B, Boschetti G, Fontaine J, Isaac S, Decullier E, Maurice C, Vaudoyer D, Gilly FN, Cotte E, Glehen O (2014) Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol 21:2608–2614CrossRefGoogle Scholar
  24. 24.
    Sugarbaker PH (2016) Preoperative assessment of cancer patients with peritoneal metastases for complete cytoreduction. Indian J Surg Oncol 7(3):295–302CrossRefGoogle Scholar
  25. 25.
    Jacobson R, Sherman SK, Dadaleh F, Turaga KK (2018 Aug) Peritoneal metastases in colorectal cancer. Ann Surg Oncol 25(8):2145–2151CrossRefGoogle Scholar
  26. 26.
    Roth L, Schneider M, Eden J, Pache B, Laminger F, Lopez-Lopez V, Steffen T et al (2018) Mutation of RAS/RAF-proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastases of colorectal origin. Pleura Peritoneum 1(Special Suppl):sA6–sA463Google Scholar
  27. 27.
    Pelz JOW, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J (2009) Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol 99:9–15.  https://doi.org/10.1002/jso.21169 CrossRefGoogle Scholar
  28. 28.
    Huang Y, Alzahrani NA, Liauw W, Arrowaili A, Morris DL (2018) Survival difference between mucinous vs. non-mucinous colorectal cancer following cytoreductive surgery and intraperitoneal chemotherapy. Int J Hyperth 21:1–7Google Scholar
  29. 29.
    Brandl A, Weiss S, von Winterfeld M, Krannich A, Feist M, Pratschke J, Raue W, Rau B (2018) Predictive value of peritoneal cancer index for survival in patients with mucinous peritoneal malignancies treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a single centre experience. Int J Hyperthermia 34(5):512–517CrossRefGoogle Scholar
  30. 30.
    Cashin PH, Mahteme H, Spång N, Syk I, Frödin JE, Torkzad M, Glimelius B, Graf W (2016) Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer 53:155–162.  https://doi.org/10.1016/j.ejca.2015.09.017 CrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of Surgical OncologyZydus HospitalAhmedabadIndia
  2. 2.Department of Surgical OncologySaifee HospitalMumbaiIndia
  3. 3.Department of Surgical OncologyMVR Cancer Centre and Research InstituteCalicutIndia
  4. 4.Department of Surgical OncologyManipal HospitalBangaloreIndia
  5. 5.Department of Surgical OncologyJehangir HospitalPuneIndia
  6. 6.Department of Surgical OncologyAll India Institute of Medical Sciences (AIIMS)New DelhiIndia
  7. 7.Department of Surgical OncologyCancer Institute, WIAChennaiIndia

Personalised recommendations